enGene Holdings Inc. Common Stock
NasdaqCM ENGN
enGene Holdings Inc. Common Stock Return on Equity (ROE) for the Trailing 12 Months (TTM) ending October 31, 2024
enGene Holdings Inc. Common Stock Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending October 31, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
Key data
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
NasdaqCM: ENGN
| CEO | Mr. Ronald H. W. Cooper |
| IPO Date | Feb. 1, 2022 |
| Location | Canada |
| Headquarters | 7171 Rue Frederick Banting |
| Employees | 31 |
| Sector | Healthcare |
| Industries | |
Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Key trends
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email